Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2016

View Archived Issues

FDA grants orphan drug designation to Ovid Therapeutics' OV-101

Pivotal phase III in Tandem1 study meets primary endpoint

Vaccinex's SIGNAL study to continue

NIH dopamine D3 receptor antagonist VK-4-116 active in substance abuse models

Ligand Pharmaceuticals patents gemcitabine derivatives

Nintedanib named orphan drug in U.S. and E.U. for SSc-ILD

Acesys Pharmatech discloses antibacterial agents

FDA names cinacalcet an orphan treatment for hyperparathyroidism in children with CKD

Akari Therapeutics' coversin granted U.S. orphan status for paroxysmal nocturnal hemoglobinuria

Drug repurposing screen identifies small-molecule inhibitors of Zika virus infection

FDA grants QIDP designation to MGB-BP-3 for C. difficile-associated diarrhea

Palobiofarma describes adenosine A2B antagonists and melatonin MT3 receptor ligands

Bristol-Myers Squibb develops NS5B inhibitors

Incyte presents FGFR-4 inhibitors

Germline mutations identified in patients with atrial fibrillation and mitral valve regurgitation

Sage Therapeutics announces GABA(A) receptor modulators

Karuna initiates tolerability proof-of-concept trial for KarXT

Chiesi discloses novel compounds for pulmonary inflammation

Inflazome closes Series A financing

PC-786 shows rapid and sustained RSV replication inhibition

GSK and Aspen announce series of agreements

Phase IIIb trials to study use of dapagliflozin for chronic kidney disease and chronic heart failure

AnTolRx obtains Series A financing for targeted nanoparticle tolerance therapeutics

Takeda Pharmaceutical presents new renin inhibitor

Sanofi and Verily Life Sciences launch Onduo joint venture

BeiGene cleared to conduct clinical trials of BGB-A317 in China

Merck KGaA launches Centinel technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...